Krystal Biotech, Inc. KRYS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 42.8%+10.2pp | 41.4%+18.8pp | 42.4%+32.3pp | 38.8%+53.3pp | 32.6%— | |
| Net margin | 53.9%+16.7pp | 52.6%+21.9pp | 53.3%+31.6pp | 40.8%-22.9pp | 37.2%— | |
| Returns | ||||||
| Return on equity | 19.9%+6.0pp | 18.9%+8.6pp | 19.7%+13.3pp | 15.6%+1.4pp | 13.9%+5.0pp | |
| Return on invested capital | 24.3%+7.1pp | 24%+12.2pp | 24.8%+20.0pp | 20.2%+25.6pp | 17.2%+34.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 9.5×-0.2× | 10×+2.7× | 10.1×+2.2× | 9.7×+0.2× | 9.6×-3.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -2.7×— | -2.9×— | -2.3×— | -2.4×— | —— | |
| Per Share | ||||||
| Book value per share | $41.85+27.0% | $40.72+28.0% | $38.14+28.7% | $34.98+23.6% | $32.96+20.8% | |
| Valuation | ||||||
| Market capitalization | $7.55B+45.4% | $7.15B+58.7% | $5.11B-1.9% | $4.15B-20.1% | $5.19B+3.2% | |
| Price / earnings | 33.6×-8.3× | 34.9×-15.6× | 25.7×-73.7× | 28.3×— | 41.9×— | |
| Price / sales | 18.1×+2.5× | 18.4×+2.9× | 13.7×-7.9× | 11.6×-19.7× | 15.6×— | |
| Price / book | 5.9×+0.6× | 5.9×+1.1× | 4.5×-1.4× | 4×-2.2× | 5.3×-1.0× | |
| EV / EBITDA | 38.3×— | 39.9×— | 28.9×— | 26.3×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Krystal Biotech, Inc.'s ratios come from?
- Every ratio is computed from Krystal Biotech, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
